Follow
Romano Danesi
Title
Cited by
Cited by
Year
Molecular basis of resistance to azole antifungals
A Lupetti, R Danesi, M Campa, M Del Tacca, S Kelly
Trends in molecular medicine 8 (2), 76-81, 2002
5722002
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ...
Cancer research 70 (11), 4528-4538, 2010
5302010
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti, M Del Tacca, V Mey, N Funel, S Nannizzi, S Ricci, ...
Cancer research 66 (7), 3928-3935, 2006
4342006
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
3442019
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy
A Sparreboom, R Danesi, Y Ando, J Chan, WD Figg
Drug Resistance Updates 6 (2), 71-84, 2003
3062003
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs
R Danesi, S Fogli, A Gennari, P Conte, M Del Tacca
Clinical pharmacokinetics 41, 431-444, 2002
2812002
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin–treated advanced non–small cell lung cancer patients
C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan, S Nannizzi, ...
Clinical cancer research 14 (6), 1797-1803, 2008
2722008
The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ...
European urology 71 (4), 680-687, 2017
2632017
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells
E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, L Marini, M Del Tacca, ...
Molecular pharmacology 68 (1), 110-118, 2005
2372005
Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
A Hamada, T Sissung, DK Price, R Danesi, CH Chau, N Sharifi, D Venzon, ...
Clinical cancer research 14 (11), 3312-3318, 2008
2312008
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ...
British journal of cancer 118 (6), 820-824, 2018
2242018
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
L Jain, CA Vargo, R Danesi, TM Sissung, DK Price, D Venzon, J Venitz, ...
Molecular cancer therapeutics 8 (9), 2496-2508, 2009
2142009
The pharmacological bases of the antiangiogenic activity of paclitaxel
G Bocci, A Di Paolo, R Danesi
Angiogenesis 16, 481-492, 2013
2032013
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
F Crea, EM Hurt, LA Mathews, SM Cabarcas, L Sun, VE Marquez, ...
Molecular cancer 10, 1-10, 2011
2022011
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
E Giovannetti, A Erozenci, J Smit, R Danesi, GJ Peters
Critical reviews in oncology/hematology 81 (2), 103-122, 2012
2012012
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate …
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi, JA Rodriguez, ...
Molecular pharmacology 73 (4), 1290-1300, 2008
1992008
Cardiac toxicity of antineoplastic anthracyclines
R Zucchi, R Danesi
Current Medicinal Chemistry-Anti-Cancer Agents 3 (2), 151-171, 2003
1982003
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer
A Falcone, G Masi, G Allegrini, R Danesi, E Pfanner, IM Brunetti, ...
Journal of clinical oncology 20 (19), 4006-4014, 2002
1912002
Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma
L Rimassa, R Danesi, T Pressiani, P Merle
Cancer Treatment Reviews 77, 20-28, 2019
1902019
Clinical pharmacology of intravitreal anti-VEGF drugs
S Fogli, M Del Re, E Rofi, C Posarelli, M Figus, R Danesi
Eye 32 (6), 1010-1020, 2018
1772018
The system can't perform the operation now. Try again later.
Articles 1–20